Cargando…
Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?
Programmed cell death protein 1 (PD-1) and its ligands, PD-L1/2, control T cell activation and tolerance. While PD-1 expression is induced upon T cell receptor (TCR) activation or cytokine signaling, PD-L1 is expressed on B cells, antigen presenting cells, and on non-immune tissues, including cancer...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468592/ https://www.ncbi.nlm.nih.gov/pubmed/34571982 http://dx.doi.org/10.3390/cells10092333 |
_version_ | 1784573710151188480 |
---|---|
author | Adorisio, Sabrina Cannarile, Lorenza Delfino, Domenico V. Ayroldi, Emira |
author_facet | Adorisio, Sabrina Cannarile, Lorenza Delfino, Domenico V. Ayroldi, Emira |
author_sort | Adorisio, Sabrina |
collection | PubMed |
description | Programmed cell death protein 1 (PD-1) and its ligands, PD-L1/2, control T cell activation and tolerance. While PD-1 expression is induced upon T cell receptor (TCR) activation or cytokine signaling, PD-L1 is expressed on B cells, antigen presenting cells, and on non-immune tissues, including cancer cells. Importantly, PD-L1 binding inhibits T cell activation. Therefore, the modulation of PD-1/PD-L1 expression on immune cells, both circulating or in a tumor microenvironment and/or on the tumor cell surface, is one mechanism of cancer immune evasion. Therapies that target PD-1/PD-L1, blocking the T cell-cancer cell interaction, have been successful in patients with various types of cancer. Glucocorticoids (GCs) are often administered to manage the side effects of chemo- or immuno-therapy, exerting a wide range of immunosuppressive and anti-inflammatory effects. However, GCs may also have tumor-promoting effects, interfering with therapy. In this review, we examine GC signaling and how it intersects with PD-1/PD-L1 pathways, including a discussion on the potential for GC- and PD-1/PD-L1-targeted therapies to “confuse” the immune system, leading to a cancer cell advantage that counteracts anti-cancer immunotherapy. Therefore, combination therapies should be utilized with an awareness of the potential for opposing effects on the immune system. |
format | Online Article Text |
id | pubmed-8468592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84685922021-09-27 Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? Adorisio, Sabrina Cannarile, Lorenza Delfino, Domenico V. Ayroldi, Emira Cells Review Programmed cell death protein 1 (PD-1) and its ligands, PD-L1/2, control T cell activation and tolerance. While PD-1 expression is induced upon T cell receptor (TCR) activation or cytokine signaling, PD-L1 is expressed on B cells, antigen presenting cells, and on non-immune tissues, including cancer cells. Importantly, PD-L1 binding inhibits T cell activation. Therefore, the modulation of PD-1/PD-L1 expression on immune cells, both circulating or in a tumor microenvironment and/or on the tumor cell surface, is one mechanism of cancer immune evasion. Therapies that target PD-1/PD-L1, blocking the T cell-cancer cell interaction, have been successful in patients with various types of cancer. Glucocorticoids (GCs) are often administered to manage the side effects of chemo- or immuno-therapy, exerting a wide range of immunosuppressive and anti-inflammatory effects. However, GCs may also have tumor-promoting effects, interfering with therapy. In this review, we examine GC signaling and how it intersects with PD-1/PD-L1 pathways, including a discussion on the potential for GC- and PD-1/PD-L1-targeted therapies to “confuse” the immune system, leading to a cancer cell advantage that counteracts anti-cancer immunotherapy. Therefore, combination therapies should be utilized with an awareness of the potential for opposing effects on the immune system. MDPI 2021-09-06 /pmc/articles/PMC8468592/ /pubmed/34571982 http://dx.doi.org/10.3390/cells10092333 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Adorisio, Sabrina Cannarile, Lorenza Delfino, Domenico V. Ayroldi, Emira Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? |
title | Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? |
title_full | Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? |
title_fullStr | Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? |
title_full_unstemmed | Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? |
title_short | Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? |
title_sort | glucocorticoid and pd-1 cross-talk: does the immune system become confused? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468592/ https://www.ncbi.nlm.nih.gov/pubmed/34571982 http://dx.doi.org/10.3390/cells10092333 |
work_keys_str_mv | AT adorisiosabrina glucocorticoidandpd1crosstalkdoestheimmunesystembecomeconfused AT cannarilelorenza glucocorticoidandpd1crosstalkdoestheimmunesystembecomeconfused AT delfinodomenicov glucocorticoidandpd1crosstalkdoestheimmunesystembecomeconfused AT ayroldiemira glucocorticoidandpd1crosstalkdoestheimmunesystembecomeconfused |